Rimekor MB, 35 mg 60pcs

Pharmacological properties. Pharmacodynamics

It has antihypoxic effect. It normalizes the energy metabolism of cells subjected to hypoxia or ischemia.

Directly influencing cardiomyocytes and brain neurons to optimize their metabolism and function.

Cytoprotective effect is caused by increase of energetic potential, activation of oxidative decarboxylation and oxygen consumption rationalization (increase of aerobic glycolysis and deceleration of fatty acids oxidation due to selective inhibition of long-chain 3-ketoacyl-CoA-thiolase).

Trimetazidine maintains myocardial contractility, prevents reduction in intracellular adenosine triphosphoric acid (ATP) and creatine phosphate.

Under acidosis it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium ions in cardiomyocytes and normalizes the intracellular concentration of potassium ions.

It reduces intracellular acidosis and increased phosphate content caused by myocardial ischemia and reperfusion.

Prevents the damaging effects of free radicals, maintains the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, increases the duration of electrical

potential, reduces the output of creatine phosphokinase from cells and the severity of ischemic myocardial damage.

With angina reduces the frequency of attacks, reduces the need to take nitrates, after 2 weeks of treatment increases tolerance to physical activity, reduces the sharp fluctuations of blood pressure.

It reduces dizziness and tinnitus of ischemic etiology. With vascular eye pathology restores the functional activity of the retina.

Pharmacokinetics

After oral administration trimetazidine is quickly and almost completely absorbed in the gastrointestinal tract.

Food intake does not affect pharmacokinetic properties of the drug. Bioavailability is 90%. Time of reaching maximum concentration in blood plasma – 3-5 hours.

During 24 hours concentration in plasma remains at the level exceeding 75% of concentration determined 11 hours after taking one tablet.

The equilibrium plasma concentration is reached approximately 60 h after the start of treatment. Distribution volume is 4.8 l/kg, the blood plasma protein binding is 16%.

It easily passes through histohematic barriers. It is excreted unchanged, mainly by the kidneys (about 60%). Period of semiejection is about 7 hours, in patients older than 65 years – about 12 hours.

Renal clearance of trimetazidine directly correlates with creatinine clearance (CK), hepatic clearance decreases with age.

Indications

Active ingredient

Composition

1 film-coated sustained release tablet contains:

The active ingredient:

Trimetazidine dihydrochloride (in terms of 100% substance) – 35.0 mg;

Auxiliary substances:

Mannitol – 13.5 mg,

Microcrystalline cellulose – 21.0 mg,

Glycolium mountain wax (montan wax) – 39.0 mg,

Methyl methacrylate, trimethylammonioethyl methacrylate chloride and ethyl acrylate copolymer [1:2:0.1] (Eudragit RS PO) – 40.0 mg, magnesium stearate – 1.5 mg;

Shell – 8.0 mg:

FD&C aluminum blue varnish #2 – 0.07%,

FD&C aluminum yellow varnish #6 – 0.77%,

Macrogol (polyethylene glycol) – 20.20%,

How to take, the dosage

Special Instructions

Rimekor MB is not intended to relieve angina attacks and is not indicated for initial therapy of unstable angina or myocardial infarction, or in preparation for hospitalization or the first days of hospitalization!!!

In the event of an angina attack, treatment should be reviewed and adapted.

In the absence of relevant clinical data, use of Rimekor MB is not recommended in patients with renal impairment with creatinine clearance less than 15 ml/min, or in patients with severe liver function impairment.

Impact on driving and operating machinery

We advise caution when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

Side effects

Frequency of side effects: very frequently (more than 1/10); frequently (more than 1/100 and less than 1/10); infrequently (more than 1/1000 and less than 1/100); rarely (more than 1/10000 and less than 1/1000); very rarely (more than 1/10000), including individual reports.

Digestive system disorders

Often: Abdominal pain, diarrhea, dyspepsia, nausea, vomiting

Cardiovascular system disorders

Rarely: orthostatic hypotension, “flushes” of blood to the face.

Central nervous system disorders

Often: dizziness, headache, asthenia.

Very rare: extrapyramidal disorders (tremor, rigidity, akinesia), reversible after discontinuation of the drug.

Skin disorders

Often: skin rash, itching, urticaria.

Overdose

There are limited data on cases of overdose.

In case of overdose, symptomatic treatment should be administered.

Similarities